A meta-analysis that included four observational studies, involving a total of 261,689 patients, showcased an increased risk of lymphoma in IBD patients administered with anti-TNFα agents, either as monotherapy or in conjunction with thiopurines (166). The gene discussed is TNF; the disease is inflammatory bowel disease.